Strategy The creator of X-COM isn't worried about old fans not vibing with his new game: 'It's successful for people who have maybe not played any strategy at all' Strategy The most exciting new ...

2001's Advance Wars is a perfect little game: Compact yet tactically rich, a purposefully limited but versatile library of units like top-heavy tanks and chonky bombers smashing together in rock-paper ...

Forever ensnared in a love-fued between 1800s literature and modern gaming, Eman Fatima tries her best to appease both her hobbies by tapping away at her keyboard and writing about her favorite games ...

Try as I might, turn-based strategy games don't usually do it for me. That's one reason I haven't yet dipped into Clair Obscur: Expedition 33, many people's favorite of the year so far. I'd almost ...

For years, account-based GTM has been sold as the fix for revenue alignment — promising better focus, more relevance, faster pipeline and tighter collaboration. Yet many organizations stall, weighed ...

RTS Dawn of War 4's 'guiding star' was the first in the series, but 'you're not trying to recreate the old game, you try to recreate the feeling' Strategy The creator of X-COM isn't worried about old ...

Over the last few years, Annapurna Interactive has built a reputation on publishing some of the most unique and experimental games in the space, from the thoughtful intergalactic exploration of Outer ...

SEATTLE — Welcome to Season 2 of Hard Turn, the show that explores life's most challenging moments and the incredible human spirit that gets us through them. In our season premiere, hosts Mary Nam and ...

Third Person Shooters Helldivers 2 players were already getting obliterated, so now it just feels like game master Joel is taking their lunch money, kicking their teeth in, and spitting in their eyes ...

Adam is a lifelong gamer who enjoys RPGs, action adventure games and a healthy helping of VR to boot. He has written for countless sites in the gaming medium, and you can find him playing the newest ...

There are two FDA-approved medications for the metabolic disorder known as MASH. Roche is paying $2.4 billion to acquire 89bio and its late-stage MASH drug, giving the Swiss pharmaceutical giant the ...

The quantum many body problem has been at the heart of much of theoretical and experimental physics over the past few decades. Even though we have understood the fundamental laws that govern the ...